Table 12.

MIC and susceptibility results for all H. influenzae isolates from Lebanon

						Susceptibility
		MIC (mg/L)				CLSI			PK/PD	EUCAST
Antimicrobial	n	50%	90%	min	max	%S	%I	%R	%S	%S	%I	%R
AMCa,b	47	0.5	2	≤0.015	2	100.0 (91.5)c	0	0 (8.5)c	100.0 (100.0)	100.0 (85.1)c	0 (0)c	0 (14.9)c
Ampicillin	47	0.5	32	0.06	>256	70.2	6.4	23.4	NA	70.2	0	29.8
Cefaclorb	47	1	4	0.03	32	95.7 (87.2)c	2.1 (2.2)c	2.1 (10.6)c	8.5	NA	NA	NA
Cefepime	47	0.03	0.06	0.03	0.06	100.0	0	0	NA	100.0	0	0
Cefixime	47	0.03	0.06	0.03	0.06	100.0	0	0	100.0	100.0	0	0
Cefpodoxime	47	0.06	0.12	0.03	0.25	100.0	0	0	100.0	100.0	0.0	0
Ceftriaxone	47	0.004	0.008	0.004	0.008	100.0	0	0	100.0	100.0	0	0
Cefuroximeb	47	0.5	1	0.015	8	95.7 (89.4)c	4.3 (2.1)c	0 (8.5)c	91.5	6.4 (6.4)c	85.1 (72.3)c	8.5 (21.3)c
Ciprofloxacin	47	0.015	0.03	0.002	0.12	100.0	0	0	100.0	100.0	0	0
Levofloxacin	46	0.06	0.12	0.015	0.5	100.0	0	0	100.0	100.0	0	0
Moxifloxacin	46	0.06	0.12	0.03	1	100.0	0	0	100.0	97.8	0	2.2

min, minimum; max, maximum; AMC, amoxicillin/clavulanic acid; S, susceptible; I, intermediate; R, resistant; NA, no breakpoint data available (NA for azithromycin and clarithromycin by EUCAST because Etest^® breakpoints in CO₂ not available).

^aPK/PD susceptibility at high dose is shown in parentheses.

^bIn clinical setting, isolates of BLNAR are considered resistant to amoxicillin/clavulanic acid, cefaclor and cefuroxime (see main text).

^cSusceptibility to amoxicillin/clavulanic acid, cefaclor and cefuroxime (data in parenthesis) due to corrections according to BLNAR (see main text).